A Randomized Double-Blind Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)

Brief description of study

This study will examen whether the investigational drug, tirzepatide, is safe and able to help study participants with nonalcoholic steatohepatitis (NASH). “Investigational” means that the drug being tested has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). The FDA is allowing the use of this drug for research. Tirzepatide is being developed to improve levels of blood sugar in adults with type 2 diabetes mellitus (T2DM)


Clinical Study Identifier: s19-01282
ClinicalTrials.gov Identifier: NCT04166773
Principal Investigator: Ira M. Jacobson.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.